Nephrology & Dialysis
Nephrology practices, dialysis center operators, and kidney disease management organizations providing renal care services.
- 6
- Verticals
Overview
Nephrology & Dialysis covers nephrology practices, dialysis-center operators, and kidney-disease management organizations. Dialysis is a consolidated duopoly — DaVita and Fresenius — serving a chronic, recurring, and largely Medicare-funded patient population.
The model combines highly recurring treatment volume with reimbursement and policy sensitivity (Medicare ESRD program, value-based kidney-care models). Demand is driven by the prevalence of chronic kidney disease and diabetes, and consolidation extends from dialysis into integrated value-based kidney care.
Market snapshot
- Market size
- ~$30B
- Growth
- ~3.9%CAGR (2017–22, nominal)
- Companies
- ~507 firms
63.3% of firms have fewer than 20 employees: 321 micro-businesses, below most mandates.
- 20–99
- 11863%
- 100–499
- 2614%
- 500+
- 4223%
A national duopoly — DaVita and Fresenius run most of the ~500 firms, ~268 employees each — sized on the dialysis-center code. Growth is steady (~3.9%/yr) on rising diabetes and kidney-disease prevalence, but the two-player structure and Medicare/MA reimbursement leave little room for new consolidation plays.
NAICS 621492. U.S. Census Bureau — 2022 Statistics of U.S. Businesses; U.S. Census Bureau — 2022 Economic Census.
Business model & economics
Revenue model
Recurring dialysis-treatment reimbursement (largely Medicare)
Key economics
- Revenue per firm
- $59,031,576
- Revenue per employee
- $209,317
- Employees per firm
- 268.4
- Recurring revenue
- High
- EBITDA margin
- Reimbursement-policy-driven
- Capex intensity
- High
thrice-weekly recurring treatment
Characteristics
- Balanced cost base — payroll is 25% of revenue, leaving room to scale margin without cutting staff
- Moderate strategic-buyer pool — 42 firms exceed 500 employees; a scaled asset has buyers, but not many
- Consolidated duopoly (DaVita, Fresenius).
- Chronic, recurring, largely Medicare-funded.
- Shift toward integrated value-based kidney care.
NAICS 621492. U.S. Census Bureau — 2022 Statistics of U.S. Businesses; U.S. Census Bureau — 2022 Economic Census.
M&A deal context
Who’s acquiring
- Dialysis majors
- Value-based kidney-care platforms
- Nephrology MSOs
What’s driving deals
- Value-based kidney-care integration.
- Chronic kidney-disease prevalence.
- Reimbursement-policy dynamics.
Verticals in this segment
Find Nephrology & Dialysis acquisition targets
Search Acquisera’s index for companies classified under Nephrology & Dialysis (4.10.13) and build a targeted deal pipeline.
Search companies